Replies to post #432025 on Amarin Corp Plc (AMRN)

[JRoon71]

A change to an existing drug typically requires new safety trials when the modification significantly alters the drug's formulation, dosage, route of administration, or intended patient population, potentially introducing new safety concerns that were not evaluated in the original clinical trials; this is especially true if the change could substantially impact the drug's safety profile, even if it's a seemingly minor modification.